Literature DB >> 3663958

Analysis of interval breast carcinomas in a randomized screening trial in Stockholm.

J Frisell1, G Eklund, L Hellström, A Somell.   

Abstract

In the interval between screening examinations, some cases of breast cancer are invariably detected clinically in patients whose mammogram was considered to be normal at the earlier screening. During the first interval in the Stockholm study, 60 interval cancers were detected, giving a rate of 1.8 cases/1000 examinations/24 months. About half of these interval cases (31/60) were true interval tumours in that no sign of them could be found on the first mammogram; the other half, non-true, were possible to trace on the first mammogram. It is mainly women under 50 who feature in the interval group, above all in the sub-group of true interval cancers (p less than 0.05). The incidence of interval cancer rises, as expected, with the length of the interval (Fig. 1). In the final six months of the 2-year interval the incidence of interval cancers had risen to 88 per cent of the cancers detected in the control group in the same period of time. The cumulative incidence of interval cancers supports the hypothesis that the distribution of sojourn time in the interval 0-2 years is approximately rectangular. This means that shortening the interval by one-half would halve the number of interval cases. If mammography becomes a wide spread screening method for early detection of breast cancer, the number of non-true interval cancers could be a feed back on the effectiveness of the screening.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663958     DOI: 10.1007/bf01806383

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

1.  Population screening for breast cancer by single-view mammography in a geographic region in Sweden.

Authors:  B Lundgren
Journal:  J Natl Cancer Inst       Date:  1979-06       Impact factor: 13.506

2.  Simplified models of screening for chronic disease: estimation procedures from mass screening programmes.

Authors:  N E Day; S D Walter
Journal:  Biometrics       Date:  1984-03       Impact factor: 2.571

3.  Prognosis in breast cancer: the relevance of clinical staging.

Authors:  A O Langlands; G R Kerr
Journal:  Clin Radiol       Date:  1978-11       Impact factor: 2.350

4.  Breast cancer missed by mammography.

Authors:  J E Martin; M Moskowitz; J R Milbrath
Journal:  AJR Am J Roentgenol       Date:  1979-05       Impact factor: 3.959

5.  Single view mammography: a simple and efficent approach to breast cancer screening.

Authors:  B Lundgren; S Jakobsson
Journal:  Cancer       Date:  1976-09       Impact factor: 6.860

6.  Significant reduction in advanced breast cancer. Results of the first seven years of mammography screening in Kopparberg, Sweden.

Authors:  L Tabár; A Gad; L Holmberg; U Ljungquist
Journal:  Diagn Imaging Clin Med       Date:  1985

7.  Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading.

Authors:  F F Parl; B P Schmidt; W D Dupont; R K Wagner
Journal:  Cancer       Date:  1984-11-15       Impact factor: 6.860

8.  Interval breast cancer: a more aggressive subset of breast neoplasias.

Authors:  R DeGroote; B F Rush; J Milazzo; M J Warden; J M Rocko
Journal:  Surgery       Date:  1983-10       Impact factor: 3.982

9.  Tumor growth, doubling times, and the inability of the radiologist to diagnose certain cancers.

Authors:  J B Buchanan; J S Spratt; L S Heuser
Journal:  Radiol Clin North Am       Date:  1983-03       Impact factor: 2.303

10.  Mammographic breast cancer screening--a randomized trial in Malmö, Sweden.

Authors:  I Andersson; L Janzon; B F Sigfússon
Journal:  Maturitas       Date:  1985-05       Impact factor: 4.342

View more
  21 in total

1.  CJS debate: Is mammography useful in average-risk screening for breast cancer?

Authors:  Muriel Brackstone; Steven Latosinsky; Elizabeth Saettler; Ralph George
Journal:  Can J Surg       Date:  2016-02       Impact factor: 2.089

2.  A comparative audit of prevalent, incident and interval cancers in the Avon breast screening programme.

Authors:  P A Sylvester; M N Vipond; E Kutt; J D Davies; A J Webb; J R Farndon
Journal:  Ann R Coll Surg Engl       Date:  1997-07       Impact factor: 1.891

3.  A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality.

Authors:  Xuelin Huang; Yisheng Li; Juhee Song; Donald A Berry
Journal:  Med Decis Making       Date:  2017-06-19       Impact factor: 2.583

4.  Calculating appropriate target cancer detection rates and expected interval cancer rates for the UK NHS Breast Screening Programme. Interval Cancer Working Group.

Authors:  S Moss; R Blanks
Journal:  J Epidemiol Community Health       Date:  1998-02       Impact factor: 3.710

5.  What should be done about interval breast cancers?

Authors:  S Field; M J Michell; M G Wallis; A R Wilson
Journal:  BMJ       Date:  1995-01-28

6.  Age-specific sensitivities of mammographic screening for breast cancer.

Authors:  P G Peer; A L Verbeek; H Straatman; J H Hendriks; R Holland
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

7.  The Stockholm breast cancer screening trial--5-year results and stage at discovery.

Authors:  J Frisell; G Eklund; L Hellström; U Glas; A Somell
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

8.  Randomized study of mammography screening--preliminary report on mortality in the Stockholm trial.

Authors:  J Frisell; G Eklund; L Hellström; E Lidbrink; L E Rutqvist; A Somell
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

9.  Interval cancer and survival in a randomized breast cancer screening trial in Stockholm.

Authors:  J Frisell; A von Rosen; M Wiege; B Nilsson; S Goldman
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

10.  The epidemiological profile of women with an interval cancer in the DOM screening programme.

Authors:  C T Brekelmans; P H Peeters; J A Faber; J J Deurenberg; H J Collette
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.